Opthea to Participate at the 2023 Euretina Congress

MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that on October 4th, Dr. Megan Baldwin, the Company’s Chief Executive Officer will be a panelist at the inaugural Euretina Innovation Spotlight forum which is part of the Organization’s 23rd Congress being held on October 5th – 8th in Amsterdam, The Netherland

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,Australia ,Melbourne ,Victoria ,Rudi Michelson ,Hershel Berry ,Megan Baldwin ,Blueprint Life Science Group ,Euretina Congress ,Investment In Biotechnology Companies ,Monsoon Communications ,Opthea Limited ,Company Media Enquiries ,Nasdaq ,Vitreous Society ,Chief Executive Officer ,Euretina Innovation Spotlight ,Treatment Modalities ,European Retina ,Biotechnology Companies ,Media Enquiries ,Iopharmaceutical Company ,Uretina ,Retinal Diseases ,Novel Therapies ,The Netherlands ,93rd Congress ,